Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 9/20 | 0.73 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.73 |
| ▸ | ITGAL | P20701 | 9/20 | 0.73 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.72 |
| ▸ | TACR1 | P25103 | 2/20 | 0.72 |
| ▸ | UBASH3B | Q8TF42 | 1/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.69 |
| ▸ | CCKBR | P32239 | 1/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzotript SCHEMBL9818252 | 1.00 | ITGB2 (0.73) | ITGB2ICAM1ITGALERAP2TACR1 | |
| SCHEMBL9466705 | 0.92 | ITGB2 (0.78) | ITGB2ICAM1ITGALERAP2TACR1 | |
| SCHEMBL30616778 | 0.92 | ITGB2 (0.78) | ITGB2ICAM1ITGALERAP2TACR1 | |
| SCHEMBL5259129 | 0.92 | ITGB2 (0.78) | ITGB2ICAM1ITGALERAP2TACR1 | |
| SCHEMBL5191302 | 0.92 | ITGB2 (0.78) | ITGB2ICAM1ITGALERAP2TACR1 | |
| SCHEMBL11870861 | 0.91 | ERAP2 (0.76) | ITGB2ICAM1ITGALERAP2CA12 | |
| SCHEMBL22206878 | 0.90 | ITGB2 (0.77) | ITGB2ICAM1ITGALERAP2TACR1 | |
| SCHEMBL22206876 | 0.90 | ITGB2 (0.77) | ITGB2ICAM1ITGALERAP2TACR1 | |
| SCHEMBL9828342 | 0.89 | ERAP2 (0.74) | ITGB2ICAM1ITGALERAP2TACR1 | |
| SCHEMBL9828348 | 0.89 | ERAP2 (0.74) | ITGB2ICAM1ITGALERAP2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023017856-A1 | MIXED POWDER, METHOD FOR MANUFACTURING ORGANIC ELECTROLUMINESCENT ELEMENT THAT USES MIXED POWDER, AND VAPOR DEPOSITION COMPOSITION | 出光興産株式会社 | 2023-02-16 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| JP-2011528275-A | — | — | 2011-11-17 | — | — | JP | claimed |
| EP-2313122-A1 | DRUG DELIVERY MEDICAL DEVICE | Micell Technologies, Inc. (US) | 2011-04-27 | — | — | EP | claimed |
| US-20100286073-A1 | COMPOUNDS AND METHODS FOR PHARMACEUTICAL USE | GENERICS (UK) LIMITED (GB) | 2010-11-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-2205229-A1 | COMPOUNDS AND METHODS FOR PHARMACEUTICAL USE | Mintails Limited (CY) | 2010-07-14 | — | — | EP | claimed |
| WO-2010009335-A1 | DRUG DELIVERY MEDICAL DEVICE | MICELL TECHNOLOGIES, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| WO-2009044202-A1 | COMPOUNDS AND METHODS FOR PHARMACEUTICAL USE | MINTAILS LIMITED (CY) | 2009-04-09 | — | — | WO | claimed |
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | claimed |
| WO-2007019221-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-1995028081-A1 | ADDRESSING BAIT AVERSION BY DISRUPTING ASSOCIATIVE LEARNING | THE MEAT INDUSTRY RESEARCH INSTITUTE OF NEW ZEALAND INC. (NZ) | 1995-10-26 | — | — | WO | claimed |
| WO-1995021622-A1 | GEL-FORMING POLYPEPTIDE DERIVATIVES | BRIGHAM & WOMEN'S HOSPITAL (US) | 1995-08-17 | — | — | WO | claimed |
| WO-1995021380-A1 | ASSAY FOR SCREENING OF RECEPTOR ANTAGONISTS | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 1995-08-10 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0422181-A1 | METHOD AND MEANS FOR INDUCING, RESP., PREVENTING CONSTRICTION OF THE PUPIL IN THE EYE | Kabi Pharmacia AB (SE) | 1991-04-17 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| WO-1990011773-A1 | METHOD AND MEANS FOR INDUCING, RESP., PREVENTING CONSTRICTION OF THE PUPIL IN THE EYE | PHARMACIA AB (SE) | 1990-10-18 | — | — | WO | claimed |
| US-4000297-A | GASTROENTERIC ACTIVITY | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1976-12-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | SI, SLC29A2, SLC29A1 | ITGB2 1873/4885ICAM1 1759/4885ITGAL 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.